WAT

Waters Corporation
NYSEHEALTHCAREDIAGNOSTICS & RESEARCH

Key Statistics

Market Cap
$40.03B
P/E Ratio
104.28
EPS
$3.91
Beta
1.18
52W High
$420.26
52W Low
$282.77
50-Day MA
$377.22
200-Day MA
$357.40
Dividend Yield
Profit Margin
3.59%
Forward P/E
28.41
PEG Ratio
1.80

About Waters Corporation

Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$4.64B
Gross Profit (TTM)$2.62B
EBITDA$1.45B
Operating Margin9.42%
Return on Equity1.92%
Return on Assets3.56%
Revenue/Share (TTM)$62.10
Book Value$155.78
Price-to-Book2.67
Price-to-Sales (TTM)8.62
EV/Revenue9.77
EV/EBITDA46.90
Quarterly Earnings Growth (YoY)-3.10%
Quarterly Revenue Growth (YoY)113.40%
Shares Outstanding$98.19M
Float$98.06M
% Insiders0.10%
% Institutions102.19%

Historical Volatility

HV 10-Day
29.69%
HV 20-Day
29.74%
HV 30-Day
29.80%
HV 60-Day
30.94%
HV Rank
34.1%

Volatility is currently contracting

Analyst Ratings

Consensus ($436.00 target)
3
Strong Buy
13
Buy
8
Hold

Latest News

Waters (WAT) Q2 Earnings and Revenues Beat Estimates

Waters (WAT) came out with quarterly earnings of $3.05 per share, beating the Zacks Consensus Estimate of $3.01 per share. This compares to earnings of $2.95 per share a year ago.

Zacks Investment Research8/4/2026Positive
Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results

Second Quarter 2026 Highlights Total reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired businesses. Organic revenue of $828 million grew 7% as reported and 9% in constant currency; the Analytical Sciences Division (ASD) delivered 8% instrument growth and double-digit chemistry consumables growth, led by low-double-digit growth in both Pharma and A&G end markets, in constant currency, as the market recovery has entered a broader phase, expanding across additional customer segments.

PRNewsWire8/4/2026Neutral
Madison Mid Cap Fund Q2 2026 Portfolio Activity

The top five contributors for the quarter were MKS, Amphenol, Arista Networks, Bio-Techne, and Waters. The bottom five detractors for the quarter were Ross Stores, Arch Capital, Copart, Gartner, and Brown & Brown. We purchased shares in Verisk Analytics, the dominant provider of data and analytics to property and casualty insurers in the U.S.

Seeking Alpha7/31/2026Neutral
Waters Corporation Is Getting Awfully Pricey

Waters Corporation remains a Hold as valuation concerns are balanced by ongoing synergy capture from its Becton, Dickinson acquisition. WAT's Q1 pro forma sales rose to $1.54B, with legacy revenue up 13% and recurring revenue surging 123%, signaling broad-based growth. Synergy realization is on track, with $55M+ cost savings and $50M revenue synergies targeted for 2026, supporting incremental EBITDA gains.

Seeking Alpha7/14/2026Positive

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on WAT and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 8/18/2026